Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

April 30, 2022

Study Completion Date

July 20, 2022

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Eribulin Mesylate

Eribulin mesylate injection is performed on Day 1 and Day 8 of each treatment cycle (21 days per cycle). Patients were treated for six cycles, except disease progression (PD) or treatment stop for other reasons, such as severe adverse effects.

DRUG

Anlotinib

12 mg Anlotinib is administered for continuous 14 days in 21 day cycles. Patients received Anlotinib untill disease progression.

Trial Locations (1)

410006

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Cancer Hospital

OTHER

NCT05206656 - Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter